GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetron Holdings Ltd (NAS:GTH) » Definitions » EV-to-EBIT

Genetron Holdings (Genetron Holdings) EV-to-EBIT : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genetron Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genetron Holdings's Enterprise Value is $0.00 Mil. Genetron Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $-97.92 Mil. Therefore, Genetron Holdings's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Genetron Holdings's EV-to-EBIT or its related term are showing as below:

GTH's EV-to-EBIT is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 20.23
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genetron Holdings's Enterprise Value for the quarter that ended in Jun. 2022 was $107.93 Mil. Genetron Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $-97.92 Mil. Genetron Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was -90.73%.


Genetron Holdings EV-to-EBIT Historical Data

The historical data trend for Genetron Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetron Holdings EV-to-EBIT Chart

Genetron Holdings Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial - - -2.19 -5.65 -0.77

Genetron Holdings Quarterly Data
Dec17 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.22 -5.65 -1.43 -1.10 -

Competitive Comparison of Genetron Holdings's EV-to-EBIT

For the Diagnostics & Research subindustry, Genetron Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetron Holdings's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetron Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genetron Holdings's EV-to-EBIT falls into.



Genetron Holdings EV-to-EBIT Calculation

Genetron Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-97.923
=0.00

Genetron Holdings's current Enterprise Value is $0.00 Mil.
Genetron Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-97.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetron Holdings  (NAS:GTH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genetron Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2022 ) =EBIT / Enterprise Value (Q: Jun. 2022 )
=-97.923/107.93008
=-90.73 %

Genetron Holdings's Enterprise Value for the quarter that ended in Jun. 2022 was $107.93 Mil.
Genetron Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-97.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetron Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genetron Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetron Holdings (Genetron Holdings) Business Description

Traded in Other Exchanges
N/A
Address
No. 8 Life Science Parkway, 1-2nd Floor, Building 11, Zone 1, Changping District, Beijing, CHN, 102206
Genetron Holdings Ltd is an oncology company in China. It is specialized in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company's operating segment includes Diagnosis and monitoring - provision for LDT services; Diagnosis and monitoring - sale of IVD products and Development services. It generates maximum revenue from the Diagnosis and monitoring - provision for LDT services segment.